Abstract
In this product focus, Dr Robert Lewis details how patiromer, a non-absorbed polymer, can appropriately and effectively be used to treat patients with chronic kidney disease, heart failure and diabetes mellitus Patiromer is a recently introduced non-absorbable polymer that is taken orally in suspension to bind potassium in the intestine, thereby reducing its absorption. It has been shown to be well tolerated and effective, both in the treatment of acute hyperkalaemia and to manage persistent hyperkalaemia. This article will detail only the latter circumstance, focusing on the potential role of patiromer in optimising long-term medical therapy for patients with chronic kidney disease, heart failure and diabetes. The mechanism of action of patiromer in vivo will be explained, and the results of clinical trials that have established its clinical utility will be reviewed. Finally, how and when this agent should be used in clinical practice will be described, with reference to recent best practice guidelines.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
